A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report
Frontiers in Oncology · 07.10.2026 · 16
DOI: 10.3389/fonc.2026.1856673 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 07.10.2026. Verfasst von Mingzhi Cha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Pingxiang People's Hospital, Pingxiang, Jiangxi, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hormone receptor-positive, human epidermal growth factor receptor 2-low (HER2-low) metastatic breast cancer (MBC) constitutes the predominant subtype of advanced breast cancer, with most patients eventually developing resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This case report describes a 64-year-old woman with hormone receptor (HR)-positive, HER2-low MBC involving lung, pleural, and lymph node metastases who achieved a remarkable and sustained radiographic complete response (rCR) to palbociclib plus fulvestrant, followed by letrozole after fulvestrant injection intolerance. The patient exhibited near-complete regression of metastatic lesions within 18 months and maintained remission for over 6 years, far exceeding the typical median progression-free survival observed in clinical trials. The prolonged remission observed underscores the existence of biologically distinct tumor subsets with exceptional sensitivity to CDK4/6 inhibition, warranting investigation into underlying molecular mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, Pingxiang People's Hospital, Pingxiang, Jiangxi, China.
- Department of Pathology, Pingxiang People's Hospital, Pingxiang, Jiangxi, China.
Zitieren
APA
Cha, M., Yi, H., Li, H., & Peng, R. (2026). A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1856673
Vancouver
Cha M, Yi H, Li H, Peng R. A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1856673
BibTeX
@article{Cha2026,
author = {Cha, Mingzhi and Yi, Hao and Li, HuiMing and Peng, Rongrong},
title = {A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1856673}
}
EUVIMED